Gloria Roldan Urgoiti
YOU?
Author Swipe
View article: A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma: Safety and Interim Phase II Analysis
A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma: Safety and Interim Phase II Analysis Open
PURPOSE Survival of patients with glioblastoma (GB) treated with standard of care (SOC) surgery, radiotherapy, and temozolomide is 15 months with progression free survival at 6 months (PFS-6M) of 53.9%. In vivo studies showed increased sur…
View article: QOL-29. Evaluating the effectiveness of a tailored exercise intervention on neuro-oncology patient outcomes
QOL-29. Evaluating the effectiveness of a tailored exercise intervention on neuro-oncology patient outcomes Open
Despite the known benefits of exercise as a supportive cancer care resource, evidence of its effectiveness in neuro-oncology is scarce and thus access to programming remains limited. This study evaluated the effectiveness of a tailored neu…
View article: “I Got My Trophy”: The Story of Implementing a Neuro-Oncology Exercise Program from the Patient and Caregiver Lens—A Qualitative Study
“I Got My Trophy”: The Story of Implementing a Neuro-Oncology Exercise Program from the Patient and Caregiver Lens—A Qualitative Study Open
The purpose of this study was to gather patient and caregiver perspectives of adult neuro-oncology patients participating in a 12-week exercise program (i.e., the Alberta Cancer Exercise-Neuro-Oncology; ACE-Neuro study). Patients and their…
View article: The feasibility of a multi-site, clinic-supported, and tailored neuro-oncology exercise program
The feasibility of a multi-site, clinic-supported, and tailored neuro-oncology exercise program Open
Background To address the lack of access to supportive cancer care resources, the purpose of this study was to examine the feasibility of a tailored exercise program for neuro-oncology patients. Methods Patients with a primary brain tumor …
View article: P17.13.A OUTCOME ANALYSIS OF PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS TREATED WITH ORAL ETOPOSIDE (VP16) IN ALBERTA, CANADA: A POPULATION-BASED RETROSPECTIVE STUDY
P17.13.A OUTCOME ANALYSIS OF PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS TREATED WITH ORAL ETOPOSIDE (VP16) IN ALBERTA, CANADA: A POPULATION-BASED RETROSPECTIVE STUDY Open
BACKGROUND Tumour recurrence in patients with gliomas is associated with short survival and there is no standard second-line therapy. Etoposide (VP16) taken orally is one of the systemic treatment options available with an acceptable safet…
View article: Feasibility and Implementation of an Oncology Rehabilitation Triage Clinic: Assessing Rehabilitation, Exercise Need, and Triage Pathways within the Alberta Cancer Exercise–Neuro-Oncology Study
Feasibility and Implementation of an Oncology Rehabilitation Triage Clinic: Assessing Rehabilitation, Exercise Need, and Triage Pathways within the Alberta Cancer Exercise–Neuro-Oncology Study Open
Individuals living with and beyond cancer face physical impairment and inactivity in survivorship. Neuro-oncology populations have especially high rates of sedentary behaviour and functional deficits, including impaired balance, motor skil…
View article: The Promise of Niacin in Neurology
The Promise of Niacin in Neurology Open
View article: Single-cell spatial immune landscapes of primary and metastatic brain tumours
Single-cell spatial immune landscapes of primary and metastatic brain tumours Open
Single-cell technologies have enabled the characterization of the tumour microenvironment at unprecedented depth and have revealed vast cellular diversity among tumour cells and their niche. Anti-tumour immunity relies on cell–cell relatio…
View article: Single-cell spatial immune landscape of primary and metastatic brain tumours
Single-cell spatial immune landscape of primary and metastatic brain tumours Open
We updated our data set, please use the new version (md5:ece00981be0f2616c1c0a57d10f3176e). All data supporting the findings of the publication "Single-cell spatial immune landscape of primary and …
View article: Single-cell spatial immune landscape of primary and metastatic brain tumours
Single-cell spatial immune landscape of primary and metastatic brain tumours Open
All data supporting the findings of the publication "Single-cell spatial immune landscape of primary and metastatic brain tumours", including masks of high-dimension tif images, single-cell segmentation, single-cell cell t…
View article: The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy
The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy Open
Background Programmed death-ligand 1 (PD-L1) expression has been shown to be prognostic in many cancer types and used in consideration of checkpoint inhibitor immunotherapy. However, there are very limited and conflicting data on the progn…
View article: ACE-Neuro: A tailored exercise oncology program for neuro-oncology patients – Study protocol
ACE-Neuro: A tailored exercise oncology program for neuro-oncology patients – Study protocol Open
View article: Cultural Differences In Breast Health: Helping all Ethnocultural Groups to Get Screened for Cancer
Cultural Differences In Breast Health: Helping all Ethnocultural Groups to Get Screened for Cancer Open
View article: ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients – Study Protocol
ACE-Neuro: A Tailored Exercise Oncology Program for Neuro-Oncology Patients – Study Protocol Open
Background Patients with primary brain tumours lack access to exercise oncology and wellness resources. The purpose of the Alberta Cancer Exercise – Neuro-Oncology (ACE-Neuro) study is to assess the feasibility of a tailored neuro-oncology…
View article: Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Open
View article: MTR-13EVALUATION OF p75 EXPRESSION AND PATTERNS OF RECURRENCE IN PATIENTS WITH MALIGNANT GLIOMAS TREATED WITH BEVACIZUMAB
MTR-13EVALUATION OF p75 EXPRESSION AND PATTERNS OF RECURRENCE IN PATIENTS WITH MALIGNANT GLIOMAS TREATED WITH BEVACIZUMAB Open
BACKGROUND: There is no standard treatment for patients with recurrent malignant gliomas (MGs) and after antiangiogenic therapy, 15% recur in a distant location suggesting the development of VEGF independent invasive mechanisms. We hypothe…